Retinitis Pigmentosa Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

 Breaking News
  • No posts were found

Retinitis Pigmentosa Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

May 18
20:34 2023
Retinitis Pigmentosa Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies,  Mechanism of Action, Route of Administration by DelveInsight
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Retinitis Pigmentosa pipeline constitutes 45+ key companies continuously working towards developing 45+ Retinitis Pigmentosa treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Retinitis Pigmentosa Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Retinitis Pigmentosa Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Retinitis Pigmentosa Market.

 

Some of the key takeaways from the Retinitis Pigmentosa Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Retinitis Pigmentosa treatment therapies with a considerable amount of success over the years. 
  • Retinitis Pigmentosa companies working in the treatment market are SanBio, Nacuity Pharmaceuticals, Ocugen, j Cyte, Aldeyra Therapeutics, Applied Genetic Technologies Corp, and others, are developing therapies for the Retinitis Pigmentosa treatment 
  • Emerging Retinitis Pigmentosa therapies such as – SB 623, NPI 001, OCU400, jCell, ADX 2191, AGTC-501, and others are expected to have a significant impact on the Retinitis Pigmentosa market in the coming years.
  • In September 2022, The strategic cooperation between the Centre for Breakthrough Medicines (CBM) and jCyte was announced in order to manufacture the cutting-edge cell therapy developed by jCyte for the treatment of retinal degenerative illnesses. In accordance with the terms of the agreement, CBM will offer Phase III clinical trial supplies and commercial therapeutic product after jCyte’s unique jCell platform technology receives approval from the Biologics Licence Application (BLA)
  • FDA Regenerative Medicine Advanced Therapy (RMAT) certification has been granted to jCell. In addition to RMATdesignation, jCell has gained Orphan Drug designation for the treatment of Retinitis Pigmentosa from the FDA and the European Medicines Agency (EMA)
  • In December 2020, In order to determine the safety of recurring intravitreal injections of human retinal progenitor cells (jCell), jCyte and the California Institute for Regenerative Medicine started a Phase II trial in adults with retinitis pigmentosa (RP)   

 

Retinitis Pigmentosa Overview

Retinitis Pigmentosa (RP) is the name given to a group of inherited retinal diseases that result in blindness and retinal degeneration. Night blindness and progressive visual field abnormalities are caused by the rod and cone photoreceptors’ bilateral progressive degradation, which is a hallmark of Retinitis Pigmentosa.

 

Get a Free Sample PDF Report to know more about Retinitis Pigmentosa Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/retinitis-pigmentosa-retinitis-pipeline-insight

 

Emerging Retinitis Pigmentosa Drugs Under Different Phases of Clinical Development Include:

  • SB 623: SanBio
  • NPI 001: Nacuity Pharmaceuticals
  • OCU400: Ocugen
  • jCell: j Cyte
  • ADX 2191: Aldeyra Therapeutics
  • AGTC-501: Applied Genetic Technologies Corp

 

Route of Administration

Retinitis Pigmentosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy 

 

Retinitis Pigmentosa Pipeline Therapeutics Assessment

  • Retinitis Pigmentosa Assessment by Product Type
  • Retinitis Pigmentosa By Stage and Product Type
  • Retinitis Pigmentosa Assessment by Route of Administration
  • Retinitis Pigmentosa By Stage and Route of Administration
  • Retinitis Pigmentosa Assessment by Molecule Type
  • Retinitis Pigmentosa by Stage and Molecule Type

 

DelveInsight’s Retinitis Pigmentosa Report covers around 45+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Retinitis Pigmentosa product details are provided in the report. Download the Retinitis Pigmentosa pipeline report to learn more about the emerging Retinitis Pigmentosa therapies

 

Some of the key companies in the Retinitis Pigmentosa Therapeutics Market include:

Key companies developing therapies for Retinitis Pigmentosa are – Sanofi, Amgen, Amarantus Bioscience Holdings, Acucela, Applied Genetic Technologies Corp, Asklepios BioPharmaceutical, Astellas Pharma, Caladrius Biosciences, Dompe Farmaceutici SpA, Dormant Projects, GenSight Biologics SA, Grupo Ferrer Internacional SA, ID Pharma, InFlectis BioScience, Ionis Pharmaceuticals, Mimetogen Pharmaceuticals, M’s Science Corp, Nanovector srl, Novartis AG, Novelion Therapeutics, ProQR Therapeutics, ReNeuron Group Plc, SanBio, Shire (Takeda Pharmaceutical), Spark Therapeutics, Sun Pharma Advanced Research Company, and others.

 

Retinitis Pigmentosa Pipeline Analysis:

The Retinitis Pigmentosa pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Retinitis Pigmentosa with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Retinitis Pigmentosa Treatment.
  • Retinitis Pigmentosa key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Retinitis Pigmentosa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Retinitis Pigmentosa market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Retinitis Pigmentosa drugs and therapies

 

Retinitis Pigmentosa Pipeline Market Drivers

Increasing Retinitis Pigmentosa Prevalence, increasing investment for healthcare infrastructure are some of the important factors that are fueling the Retinitis Pigmentosa Market.

 

Retinitis Pigmentosa Pipeline Market Barriers

However, side-effects associated with the treatment of Retinitis Pigmentosa, limited treatment options for retinitis pigmentosa and other factors are creating obstacles in the Retinitis Pigmentosa Market growth.

 

Scope of Retinitis Pigmentosa Pipeline Drug Insight    

  • Coverage: Global
  • Key Retinitis Pigmentosa Companies: SanBio, Nacuity Pharmaceuticals, Ocugen, j Cyte, Aldeyra Therapeutics, Applied Genetic Technologies Corp, and others
  • Key Retinitis Pigmentosa Therapies: SB 623, NPI 001, OCU400, jCell, ADX 2191, AGTC-501, and others
  • Retinitis Pigmentosa Therapeutic Assessment: Retinitis Pigmentosa current marketed and Retinitis Pigmentosa emerging therapies
  • Retinitis Pigmentosa Market Dynamics: Retinitis Pigmentosa market drivers and Retinitis Pigmentosa market barriers 

 

Request for Sample PDF Report for Retinitis Pigmentosa Pipeline Assessment and clinical trials

 

Table of Contents

1

Retinitis Pigmentosa Report Introduction

2

Retinitis Pigmentosa Executive Summary

3

Retinitis Pigmentosa Overview

4

Retinitis Pigmentosa- Analytical Perspective In-depth Commercial Assessment

5

Retinitis Pigmentosa Pipeline Therapeutics

6

Retinitis Pigmentosa Late Stage Products (Phase II/III)

7

Retinitis Pigmentosa Mid Stage Products (Phase II)

8

Retinitis Pigmentosa Early Stage Products (Phase I)

9

Retinitis Pigmentosa Preclinical Stage Products

10

Retinitis Pigmentosa Therapeutics Assessment

11

Retinitis Pigmentosa Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Retinitis Pigmentosa Key Companies

14

Retinitis Pigmentosa Key Products

15

Retinitis Pigmentosa Unmet Needs

16 

Retinitis Pigmentosa Market Drivers and Barriers

17

Retinitis Pigmentosa Future Perspectives and Conclusion

18

Retinitis Pigmentosa Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Related Articles

Calendar

June 2023
M T W T F S S
 1234
567891011
12131415161718
19202122232425
2627282930  

Categories